Kezar Life Sciences, Inc. (NASDAQ:KZR) Short Interest Update

Kezar Life Sciences, Inc. (NASDAQ:KZR) was the target of a significant decline in short interest in February. As of February 28th, there was short interest totalling 47,000 shares, a decline of 61.0% from the February 13th total of 120,600 shares. Based on an average daily volume of 36,700 shares, the days-to-cover ratio is presently 1.3 days. Approximately 0.8% of the shares of the stock are short sold.

Institutional Investors Weigh In On Kezar Life Sciences

Several hedge funds have recently added to or reduced their stakes in the business. Stonepine Capital Management LLC increased its position in Kezar Life Sciences by 42.0% in the 3rd quarter. Stonepine Capital Management LLC now owns 1,491,305 shares of the company’s stock valued at $1,153,000 after acquiring an additional 440,853 shares during the period. Ikarian Capital LLC grew its stake in shares of Kezar Life Sciences by 23.0% in the third quarter. Ikarian Capital LLC now owns 1,068,992 shares of the company’s stock worth $827,000 after purchasing an additional 200,000 shares during the last quarter. Geode Capital Management LLC increased its holdings in Kezar Life Sciences by 15.0% in the third quarter. Geode Capital Management LLC now owns 626,912 shares of the company’s stock valued at $485,000 after purchasing an additional 81,678 shares during the period. Peapod Lane Capital LLC bought a new position in Kezar Life Sciences during the 4th quarter worth $833,000. Finally, Shay Capital LLC bought a new position in Kezar Life Sciences during the 4th quarter worth $398,000. 67.90% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently issued reports on KZR. Wells Fargo & Company lowered their price target on Kezar Life Sciences from $11.00 to $9.00 and set an “equal weight” rating for the company in a report on Thursday, December 19th. William Blair reiterated an “outperform” rating on shares of Kezar Life Sciences in a research report on Friday, February 28th. Finally, HC Wainwright restated a “neutral” rating on shares of Kezar Life Sciences in a research report on Monday, December 2nd.

Kezar Life Sciences Trading Down 0.9 %

Kezar Life Sciences stock traded down $0.06 during trading hours on Thursday, hitting $5.81. The stock had a trading volume of 2,185 shares, compared to its average volume of 65,311. The business’s 50 day simple moving average is $6.20 and its 200-day simple moving average is $6.71. Kezar Life Sciences has a one year low of $5.20 and a one year high of $10.40. The stock has a market cap of $42.35 million, a price-to-earnings ratio of -0.44 and a beta of 0.49. The company has a quick ratio of 7.65, a current ratio of 7.65 and a debt-to-equity ratio of 0.05.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.